In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
about
Use of antibiotics in the treatment of Crohn's diseaseUse of rifaximin in gastrointestinal and liver diseasesEffect of rifaximin on gut microbiota composition in advanced liver disease and its complicationsA randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulenceThe challenges posed by reemerging Clostridium difficile infection.A Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionHigh frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study.Recurrent Clostridium difficile infection: From colonization to cure.In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.Antibiotic-associated diarrhoea.Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.Clostridium difficile: recent epidemiologic findings and advances in therapy.New advances in the treatment of Clostridium difficile infection (CDI)Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.Rifaximin in the treatment of hepatic encephalopathy.Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.Biologic properties and clinical uses of rifaximin.Treatment of refractory and recurrent Clostridium difficile infection.Rifaximin: recent advances in gastroenterology and hepatologyEfficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials.Rifaximin: beyond the traditional antibiotic activity.Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.Fecal Microbiota Transplant: Treatment Options for Clostridium difficile Infection in the Intensive Care Unit.A meta-analysis of the use of rifaximin to prevent travellers' diarrhoea.Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulationMultidrug resistance in European Clostridium difficile clinical isolates.Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin.Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients.Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations.
P2860
Q22241216-C3E522AB-47CF-4062-BA31-DC009B6D8E47Q26740201-5D485668-7CFC-494E-8222-E233103338CBQ26775927-5B264769-9A3D-4818-BB7E-E07E25559F6DQ28295210-6F0839A3-2724-4540-9F1B-D7CD00C850BFQ30229530-0B87CAF5-9B99-42F9-91B9-2ADA41437029Q30240264-2BB53A0A-152A-4041-9243-6DC6DF5F1AD7Q33641352-270FDF57-F8F4-4FFD-8E09-AB7A43933B46Q34409185-45F49919-024C-40F2-8C28-104F93F2BD0FQ34525343-B5FD86F8-DF33-4875-B31E-9FAE1AC35A74Q34557101-CD921C18-BB0C-44FE-8FE8-A5110FABA08BQ35550741-E8086EDA-7619-40AD-AEA5-0E7B63350664Q35822541-5A58F8C5-5CE9-46B7-B2AF-A7B9FA956AD7Q35912682-2F34C8CB-93FE-49ED-B334-F3D8F0DEE2A8Q36108490-0A9540E4-C86E-4E38-B66B-66CB7E764DC1Q36404922-8FB86E49-BE40-4B33-A054-7AA6AC12C6FBQ36446885-D221F628-0AE8-4D59-BB94-C29903FDBCCBQ36482832-7EF65508-BF9B-42AF-AF69-743699A64EB9Q36861661-C87BF7C4-72D0-4BBB-BD90-F3420011EF56Q37052819-01C39CB3-EEC5-459B-ADF3-0356E8146B6FQ37145568-21903445-2190-4968-BC18-D7BC7F4062ACQ37203899-76F01D5A-1D49-4F8C-960F-7863C2B3102DQ37355818-B85C6ABD-49B7-4D4A-A58F-BBA0FF41CD86Q37564122-F89DF59E-2C24-48C5-9579-1FB83651AE86Q37768415-2D91701A-0B13-45EB-B723-E83AD16019ECQ37827877-AC261CBD-1AC9-4F99-B323-F6D746FEB1DBQ37866629-EEE449A1-A96A-4BDF-A4D5-14B4096876B0Q38074951-15D21399-B96A-45DC-99C7-271F675A19EFQ38078988-09ED8670-AE60-453A-9F35-F7D2E1C952D2Q38237218-4534D948-BFDD-4F18-8637-2378F9993A0DQ38375923-9CF5815B-F5A7-4DFD-ADDB-1631AF1EA3A2Q38542515-D23DF9B9-6DEC-40D2-BFC7-01640999140CQ38684559-29A34A70-1F0D-4FEB-A5F8-55A1A234CBECQ38692607-141D7694-9593-44E9-8494-02C6E8BC5F6EQ39455595-2ED73323-0006-44BE-B773-18572D7DFC5CQ39727030-45E24163-B1CC-4728-8AB2-B251789CACC4Q40438125-1F02DA5E-2A07-42C1-8DF1-7694140463D6Q41336833-68A21031-250A-47F2-8212-59F86D977EAEQ41983988-7E7463A6-34F8-4D70-A2FF-A039B7202226Q41990739-9D30915E-A377-485D-9699-DA180D9F9F5BQ46604531-7647435F-210E-455E-A88F-5D14F72717E2
P2860
In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro activity of rifaximin ...... ing ammonia-producing species.
@ast
In vitro activity of rifaximin ...... ing ammonia-producing species.
@en
In vitro activity of rifaximin ...... ing ammonia-producing species.
@nl
type
label
In vitro activity of rifaximin ...... ing ammonia-producing species.
@ast
In vitro activity of rifaximin ...... ing ammonia-producing species.
@en
In vitro activity of rifaximin ...... ing ammonia-producing species.
@nl
prefLabel
In vitro activity of rifaximin ...... ing ammonia-producing species.
@ast
In vitro activity of rifaximin ...... ing ammonia-producing species.
@en
In vitro activity of rifaximin ...... ing ammonia-producing species.
@nl
P2093
P356
P1433
P1476
In vitro activity of rifaximin ...... ing ammonia-producing species.
@en
P2093
P304
P356
10.1159/000007297
P577
2000-07-01T00:00:00Z